KYMR
KYMR
US5015751044
Kymera Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 39.211.000 47.072.000
16.7%
Cost of Revenue -- --
--
Gross Profit -- --
--
384.755.000 303.782.000
26.7%
Operating Income -345.544.000 -256.710.000
34.6%
Pretax Income -311.351.000 -223.858.000
39.1%
Net Income Common Stockholders -311.351.000 -223.858.000
39.1%
-- --
--
-- --
--
ende